sulfasalazine has been researched along with Adenocarcinoma in 14 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Immunodeficient mice were inoculated intrafemorally with the human breast adenocarcinoma cell line MDA-MB-231, then treated 14days later via mini-osmotic pumps inserted intraperitoneally with sulfasalazine, (S)-4-carboxyphenylglycine, or vehicle." | 7.80 | Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. ( Seidlitz, EP; Singh, G; Ungard, RG, 2014) |
| "Long-term sulfasalazine administration reduced proliferative CD44v9(+) cells and increased the degree of differentiation of adenocarcinomas." | 3.83 | Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer. ( Hasegawa, H; Kameyama, K; Kitagawa, Y; Nagano, O; Okabayashi, K; Saya, H; Seishima, R; Shimoda, M; Tsuruta, M, 2016) |
| " Immunodeficient mice were inoculated intrafemorally with the human breast adenocarcinoma cell line MDA-MB-231, then treated 14days later via mini-osmotic pumps inserted intraperitoneally with sulfasalazine, (S)-4-carboxyphenylglycine, or vehicle." | 3.80 | Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain. ( Seidlitz, EP; Singh, G; Ungard, RG, 2014) |
| " Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance." | 2.43 | Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? ( Mulder, CJ; van Bodegraven, AA, 2006) |
| "In sum, we demonstrate how breast cancer bone metastases upregulate a cystine/glutamate co-transporter to elevate extracellular glutamate." | 1.43 | The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain. ( BassiriRad, NM; Bui, L; Doyle, T; Forte, BL; Largent-Milnes, TM; Mantyh, PW; Neumann, WL; Salvemini, D; Slosky, LM; Staatz, WD; Symons, AM; Thompson, M; Vanderah, TW, 2016) |
| "The risk of colorectal cancer was not increased, either in the total group of patients or in patients with colonic Crohn's disease exclusively (standardized morbidity ratio, 1." | 1.32 | Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. ( Binder, V; Jess, T; Langholz, E; Munkholm, P; Winther, KV, 2004) |
| "Spontaneous colitis and colon cancer in the cotton-top tamarin have been shown to resemble human ulcerative colitis and its associated cancer." | 1.29 | A prospective study of the epidemiology of colitis and colon cancer in cotton-top tamarins (Saguinus oedipus). ( Ausman, LM; Johnson, LD; King, NW; Sehgal, PK, 1996) |
| "An increased incidence of colonic cancer is associated with chronic inflammatory bowel disease." | 1.28 | The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. ( Crouch, R; Davis, AE; Patterson, F, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shitara, K | 1 |
| Doi, T | 1 |
| Nagano, O | 3 |
| Fukutani, M | 1 |
| Hasegawa, H | 2 |
| Nomura, S | 1 |
| Sato, A | 1 |
| Kuwata, T | 1 |
| Asai, K | 1 |
| Einaga, Y | 1 |
| Tsuchihashi, K | 2 |
| Suina, K | 1 |
| Maeda, Y | 1 |
| Saya, H | 3 |
| Ohtsu, A | 1 |
| Wada, T | 1 |
| Ishimoto, T | 1 |
| Seishima, R | 2 |
| Yoshikawa, M | 1 |
| Oshima, H | 1 |
| Oshima, M | 1 |
| Masuko, T | 1 |
| Wright, NA | 1 |
| Furuhashi, S | 1 |
| Hirashima, K | 1 |
| Baba, H | 1 |
| Kitagawa, Y | 2 |
| Ungard, RG | 1 |
| Seidlitz, EP | 1 |
| Singh, G | 1 |
| Okabayashi, K | 1 |
| Tsuruta, M | 1 |
| Shimoda, M | 1 |
| Kameyama, K | 1 |
| Slosky, LM | 1 |
| BassiriRad, NM | 1 |
| Symons, AM | 1 |
| Thompson, M | 1 |
| Doyle, T | 1 |
| Forte, BL | 1 |
| Staatz, WD | 1 |
| Bui, L | 1 |
| Neumann, WL | 1 |
| Mantyh, PW | 1 |
| Salvemini, D | 1 |
| Largent-Milnes, TM | 1 |
| Vanderah, TW | 1 |
| Ohara, G | 1 |
| Satoh, H | 1 |
| Kohno, M | 1 |
| Goto, D | 1 |
| Sumida, T | 1 |
| Hizawa, N | 1 |
| Jess, T | 1 |
| Winther, KV | 1 |
| Munkholm, P | 1 |
| Langholz, E | 1 |
| Binder, V | 1 |
| van Bodegraven, AA | 1 |
| Mulder, CJ | 1 |
| Lay, JD | 1 |
| Hong, CC | 1 |
| Huang, JS | 1 |
| Yang, YY | 1 |
| Pao, CY | 1 |
| Liu, CH | 1 |
| Lai, YP | 1 |
| Lai, GM | 1 |
| Cheng, AL | 1 |
| Su, IJ | 1 |
| Chuang, SE | 1 |
| Johnson, WR | 1 |
| Hughes, ES | 1 |
| McDermott, FT | 1 |
| Polglase, AL | 1 |
| Pihl, EA | 1 |
| Johnson, LD | 1 |
| Ausman, LM | 1 |
| Sehgal, PK | 1 |
| King, NW | 1 |
| Davis, AE | 1 |
| Patterson, F | 1 |
| Crouch, R | 1 |
| Mason, JB | 1 |
| Hall, MJ | 1 |
| Thomas, WE | 1 |
| Cooper, BT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164] | Phase 3 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for sulfasalazine and Adenocarcinoma
| Article | Year |
|---|---|
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Colonic Neoplasms; Humans; Inflammatory Bow | 2006 |
Inflammatory bowel disease--where are we? A review of ulcerative colitis and Crohn's disease, highlighting the problems of aetiology, epidemiology, clinical factors and management.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Colectomy; Colitis, Ulcerative; Colonic Neoplasms; Crohn Di | 1982 |
1 trial available for sulfasalazine and Adenocarcinoma
| Article | Year |
|---|---|
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviv | 2017 |
11 other studies available for sulfasalazine and Adenocarcinoma
| Article | Year |
|---|---|
Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.
Topics: Adenocarcinoma; Amino Acid Transport System y+; Animals; Biomarkers, Tumor; Cell Transformation, Neo | 2013 |
Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoates; Bone and Bones; Breast | 2014 |
Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.
Topics: Adenocarcinoma; Adult; Aged; Cadherins; CDX2 Transcription Factor; Cell Differentiation; Cell Prolif | 2016 |
The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiporters; Bone Neoplasms; Breas | 2016 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interaction | 2009 |
Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hor | 2004 |
Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Cell L | 2007 |
A prospective study of the epidemiology of colitis and colon cancer in cotton-top tamarins (Saguinus oedipus).
Topics: Adenocarcinoma; Animals; Body Weight; Campylobacter Infections; Colitis; Colonic Neoplasms; Disease | 1996 |
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.
Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Cocarcinogenesis; Colonic Neoplasms; Dimethylhydrazin | 1992 |
Folate, colitis, dysplasia, and cancer.
Topics: Adenocarcinoma; Adult; Colitis, Ulcerative; Colonic Neoplasms; Female; Folic Acid Deficiency; Humans | 1989 |
Gastrocnemius myositis in a patient with inflammatory bowel disease.
Topics: Adenocarcinoma; Adult; Colectomy; Colon; Colonic Neoplasms; Crohn Disease; Female; Humans; Myositis; | 1985 |